CanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of…
Browsing: CanSino Biologics Inc
On August 16, 2026, CanSino Biologics Inc. (“CanSinoBIO”; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its…
On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company’s ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)…
– Selection Day and Kick-off Ceremony Successfully Held at KTSP Over 1,000 Children Registered to Experience the Joy of Fencing…
CanSino Biologics Inc. (688185.SH/06185.HK) released its first-quarter 2026 results, reflecting a positive operational momentum. Revenue for the quarter totaled RMB…
CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by…
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies,…